Allergy Immunotherapy Advances: HDM Market Analysis

DelveInsight’s “Pancreatic Cancer Pipeline Insight, 2025,” report delivers extensive analysis on over 170 companies and more than 200 pipeline drugs in the Pancreatic Cancer treatment arena. It includes thorough profiles of Pancreatic Cancer pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Pancreatic Cancer Pipeline therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Stay ahead with the latest insights! Obtain DelveInsight’s thorough Pancreatic Cancer Pipeline Report to explore emerging treatments, key Pancreatic Cancer Companies, and future Pancreatic Cancer treatment landscapes @ Pancreatic Cancer Pipeline Outlook Report

Key Takeaways from the Pancreatic Cancer Pipeline Report

• On August 28, 2025, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins disclosed a Phase 2 trial of NC410 and FOLFIRINOX combined with Nivolumab with or without Ipilimumab in treatment-naive, metastatic Pancreatic Cancer patients.
• On August 27, 2025, Joseph J. Cullen conducted a study incorporating 75 grams of ascorbate (vitamin C, referred to as pharmacological ascorbate due to the high dose) into standard therapy. The ascorbate is delivered intravenously via an arm vein.
• On August 26, 2025, Ruijin Hospital organized an open, single-center, exploratory clinical trial to assess the safety and effectiveness of HRS-4642 combined with gemcitabine and albumin-bound paclitaxel for neoadjuvant and adjuvant therapy in Pancreatic Cancer.
• DelveInsight’s Pancreatic Cancer pipeline report illustrates a vibrant arena with over 170 active contributors developing more than 200 pipeline treatments for Pancreatic Cancer care.
• The prominent Pancreatic Cancer Companies include Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others.
• Promising Pancreatic Cancer Pipeline Therapies include Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004), and Gemcitabine, and others.

Stay updated with the latest pipeline overview for Pancreatic Cancer. Gain insights into clinical trials, emerging treatments, and key companies via DelveInsight @ Pancreatic Cancer Treatment Drugs

Pancreatic Cancer Emerging Drugs Profile

• Pamrevlumab: FibroGen Pamrevlumab is a potential pioneering antibody developed by FibroGen that blocks the function of connective tissue growth factor (CTGF), a key player in fibrotic and proliferative conditions marked by persistent and excessive scarring that can cause organ dysfunction and failure. The U.S. Food and Drug Administration has awarded Orphan Drug Designation and Fast Track status to Pamrevlumab for Pancreatic Cancer patients. It is currently in Phase III clinical trials for Pancreatic Cancer.
• Masitinib: AB Science Masitinib (AB-1010) is an experimental drug for metastatic Pancreatic Cancer. The candidate is taken orally. It competes at the ATP-binding site. It inhibits wild-type forms of c-KIT, Fyn, Lyn tyrosine kinase, and platelet-derived growth factor receptor alpha and beta. Masitinib is a selective inhibitor targeting KIT. It is under Phase III evaluation.
• Glufosfamide: Eleison Pharmaceuticals LLC. Glufosfamide links the active component of ifosfamide, from the alkylator class of chemotherapies, with a glucose molecule. Due to its glucose part and tumors’ higher glucose demand, glufosfamide may preferentially enter tumors over most healthy tissues. Inside cells, the glucose-alkylator bond breaks to release the active agent. The drug is in Phase III trials for Pancreatic Cancer.
• Quemliclustat: Arcus Biosciences, Inc. Quemliclustat is a potent and selective small molecule from Arcus Biosciences. It inhibits CD73, preventing adenosine production. Reducing adenosine restores immune function. The candidate is given intravenously and orally. It is in Phase III clinical trials.
• CT041: CARsgen Therapeutics CT041 is a potential first-in-class autologous chimeric antigen receptor CAR T-cell candidate targeting CLDN18.2 protein. CT041 addresses CLDN18.2 positive solid tumors, focusing on Pancreatic Cancer. The candidate is in Phase II.
• DK210: DEKA Biosciences DK210 (EGFR) is the initial experimental therapeutic from Deka’s platform, merging full-strength IL-2 and high-affinity IL-10 cytokines. While IL-2 can be toxic, pairing with IL-10 reduces toxicity and boosts potency, offering a more tolerable and effective option. It is the first in Deka’s DiakinesTM platform, which links cytokines to a single chain variable fragment (scFv) targeting system for precise tissue delivery. The scFv framework also enhances efficacy, safety, and production. The candidate is in Phase I for Pancreatic Cancer.
• CT7001: Carrick Therapeutics Samuraciclib is the most advanced CDK7 inhibitor in clinical development. Blocking CDK7 is a promising strategy as it controls transcription of cancer genes, drives unchecked cell division, and fosters resistance to hormone therapy. Samuraciclib has shown a good safety profile and promising results in early trials. Beyond breast cancer, it has potential in prostate, Pancreatic, ovarian, and colorectal cancers. Samuraciclib received Fast Track designation from the U.S. Food and Drug Administration (FDA) for combination with fulvestrant in CDK4/6i resistant HR+, HER2- advanced breast cancer. Carrick partners with Roche, Menarini Group, and Arvinas/Pfizer to test samuraciclib with Roche’s oral SERD giredestrant, Menarini’s oral SERD elacestrant, and Arvinas/Pfizer’s PROTAC ER degrader vepdegestrant (ARV-471) in late-stage CDK4/6i resistant HR+, HER2- metastatic breast cancer. The drug is in preclinical development for Pancreatic Cancer.

The Pancreatic Cancer Pipeline report provides insights into

• The report furnishes comprehensive details on organizations advancing therapies for Pancreatic Cancer, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Pancreatic Cancer management.
• Pancreatic Cancer Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Pancreatic Cancer Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic collaborations), licensing deals, and funding information to drive future growth in the Pancreatic Cancer market.

Explore innovative treatments and clinical trials in the Pancreatic Cancer Pipeline. Obtain DelveInsight’s detailed report today! @ Pancreatic Cancer Drugs

Pancreatic Cancer Companies Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others

Pancreatic Cancer pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pancreatic Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Reveal the future of Pancreatic Cancer Treatment. Learn about emerging drugs, pipeline advancements, and key companies with DelveInsight’s expert analysis @ Pancreatic Cancer Market Drivers and Barriers

Scope of the Pancreatic Cancer Pipeline Report

• Coverage- Global
• Pancreatic Cancer Companies- Fibrogen, AB Science, Eleison Pharmaceuticals LLC, Janssen Pharmaceuticals, CARsgen Therapeutics, Arcus Biosciences, Inc., Chia Tai Tianqing Pharmaceutical Group, Innovent Biologics, Amgen, Biomea Fusion, Prestige Biopharma Limited, Bristol-Myers Squibb, GlaxoSmithKline, Incyte Corporation, Helix BioPharma, Genentech, Inc., ENB Therapeutics, Carrick Therapeutics, Avenge Bio, DEKA Biosciences, Keymed Biosciences, Pfizer, Redx Pharma Plc, and AIM ImmunoTech Inc., and others.
• Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
• Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Pancreatic Cancer drug development? Find out in DelveInsight’s exclusive Pancreatic Cancer Pipeline Report-access it now! @ Pancreatic Cancer Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Pancreatic Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Pamrevlumab: FibroGen
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. CT041: CARsgen Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. DK210: DEKA Biosciences
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pancreatic Cancer Key Companies
21. Pancreatic Cancer Key Products
22. Pancreatic Cancer- Unmet Needs
23. Pancreatic Cancer- Market Drivers and Barriers
24. Pancreatic Cancer- Future Perspectives and Conclusion
25. Pancreatic Cancer Analyst Views
26. Pancreatic Cancer Key Companies
27. Appendix

About Us

DelveInsight is a premier market research and consulting firm focused on healthcare, offering high-quality intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “PARP Inhibitor Pipeline Insights 2025” report offers extensive analysis on over 30 companies and more than 30 pipeline drugs in the PARP Inhibitor treatment landscape. It features in-depth profiles of PARP Inhibitor pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses PARP Inhibitor therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Obtain DelveInsight’s thorough PARP Inhibitor Pipeline Report to explore emerging treatments, key Companies, and future treatment landscapes @ PARP Inhibitor Pipeline Outlook Report

Key Takeaways from the PARP Inhibitor Pipeline Report

• On August 28, 2025, AstraZeneca disclosed a Phase I/IIa modular, open-label, multi-center trial of AZD5335 given alone or with other anti-cancer agents in patients with advanced solid tumors.
• On August 26, 2025, Marc Dall’Era, MD conducted a Phase II trial examining niraparib’s effectiveness before surgery in patients with localized high-risk prostate cancer and DNA repair pathway alterations. Niraparib may inhibit tumor growth by blocking enzymes essential for cell proliferation.
• On August 26, 2025, EMD Serono Research & Development Institute, Inc. announced a trial to evaluate tuvusertib’s impact and safety when combined with niraparib or lartesertib in patients with epithelial ovarian cancer, and to compare tuvusertib alone versus in combination. Participants will have progressed on a prior PARP inhibitor. The main goals are to measure response rates and safety through adverse events.
• DelveInsight’s PARP Inhibitor pipeline report showcases a dynamic field with over 30 active contributors developing more than 30 pipeline treatments for PARP Inhibitor care.
• The top PARP Inhibitor Companies include TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others.
• Promising PARP Inhibitor Therapies include Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin, and others.

Access DelveInsight’s in-depth PARP Inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ PARP Inhibitor Clinical Trials and Studies

PARP Inhibitor Emerging Drugs Profile

• Pamiparib: BeiGene Pamiparib (BGB-290) is an experimental small molecule inhibitor of PARP1 and PARP2. Pamiparib is under evaluation as a standalone treatment in key clinical trials in China for recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is in global development as monotherapy and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for various solid tumor types.

The PARP Inhibitor Pipeline report provides insights into

• The report delivers comprehensive details on firms advancing therapies for PARP Inhibitor, including the cumulative treatments each company is developing.
• It reviews diverse therapeutic candidates categorized into initial, intermediate, and advanced development stages for PARP Inhibitor management.
• PARP Inhibitor Companies are focused on precision therapeutics with ongoing and paused (inactive or terminated) programs.
• PARP Inhibitor Drugs in development, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive examination of partnerships (business alliances and academic ties), licensing arrangements, and funding details to propel future progress in the PARP Inhibitor market.

Get a detailed analysis of the latest innovations in the PARP Inhibitor pipeline. Explore DelveInsight’s expert-driven report today! @ PARP Inhibitor Unmet Needs

PARP Inhibitor Companies TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others.

PARP Inhibitors pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

PARP Inhibitor Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Obtain DelveInsight’s latest report to gain strategic insights into upcoming PARP Inhibitor Therapies and key Developments @ PARP Inhibitor Market Drivers and Barriers, and Future Perspectives

Scope of the PARP Inhibitor Pipeline Report

• Coverage- Global
• PARP Inhibitor Companies- TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others
• PARP Inhibitor Therapies- Vismodegib, Atezolizumab, Olaparib Pill, AZD6738, JPI-547, Rucaparib, Durvalumab, Cisplatin, and others.
• PARP Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• PARP Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive PARP Inhibitor Pipeline Report-access it now! @ PARP Inhibitor Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. PARP Inhibitors: Overview
4. Structure
5. Mechanism of Action
6. Pipeline Therapeutics
7. Comparative Analysis
8. Therapeutic Assessment
9. Assessment by Product Type
10. Assessment by Stage and Product Type
11. Assessment by Route of Administration
12. Assessment by Stage and Route of Administration
13. Assessment by Molecule Type
14. Assessment by Stage and Molecule Type
15. PARP Inhibitors – DelveInsight’s Analytical Perspective
16. In-depth Commercial Assessment
17. PARP Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
18. PARP Inhibitors Collaboration Deals
19. Company-Company Collaborations (Licensing / Partnering) Analysis
20. Company-University Collaborations (Licensing / Partnering) Analysis
21. Late Stage Products (Phase III)
22. Comparative Analysis
23. Pamiparib: BeiGene
24. Product Description
25. Research and Development
26. Product Development Activities
27. Drug profiles in the detailed report…..
28. Mid Stage Products (Phase II)
29. Comparative Analysis
30. Drug Name: Company Name
31. Product Description
32. Research and Development
33. Product Development Activities
34. Drug profiles in the detailed report…..
35. Pre-clinical and Discovery Stage Products
36. Comparative Analysis
37. Drug Name: Company Name
38. Product Description
39. Research and Development
40. Product Development Activities
41. Drug profiles in the detailed report…..
42. Inactive Products
43. Comparative Analysis
44. PARP Inhibitors Key Companies
45. PARP Inhibitors Key Products
46. PARP Inhibitors- Unmet Needs
47. PARP Inhibitors- Market Drivers and Barriers
48. PARP Inhibitors- Future Perspectives and Conclusion
49. PARP Inhibitors Analyst Views
50. PARP Inhibitors Key Companies
51. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Colorectal Cancer Pipeline Insight 2025” report delivers extensive analysis on over 195 companies and more than 200 pipeline drugs in the Colorectal Cancer treatment arena. It includes thorough profiles of Colorectal Cancer pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Colorectal Cancer therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Explore our cutting-edge advancements in Colorectal Cancer studies. Get more details on our pioneering pipeline now! @ Colorectal Cancer Pipeline Outlook

Key Takeaways from the Colorectal Cancer Pipeline Report

• On August 29, 2025, Merck Sharp & Dohme LLC disclosed a phase 3 trial of Pembrolizumab (MK-3475) compared to chemotherapy in Chinese patients with Stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Colorectal Cancer (MK-3475-C66).
• On August 28, 2025, Oncoinvent AS conducted a phase 1/2a open-label study to assess the dosage, safety, tolerability, and effectiveness of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in individuals with peritoneal carcinomatosis (PC) from colorectal carcinoma after complete CRS (cytoreduction score CC-0) and HIPEC.
• DelveInsight’s Colorectal Cancer pipeline report illustrates a vibrant arena with over 195 active contributors developing more than 200 pipeline treatments for Acute Lymphocytic Leukemia care.
• The prominent Colorectal Cancer Companies include Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
• Promising Colorectal Cancer Therapies include Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.

Stay updated on the latest innovations in Colorectal Cancer treatments. Access for updates and join the advancement in care @ Colorectal Cancer Clinical Trials Assessment

Colorectal Cancer Emerging Drugs Profile

• XL092 : Exelixis XL092 is an experimental small molecule, oral tyrosine kinase inhibitor (TKI) that blocks the function of receptor tyrosine kinases implicated in cancer progression and metastasis, such as VEGF receptors, MET, AXL, and MER. These kinases play roles in both normal cell processes and pathological events like tumor formation, spread, and blood vessel growth. It is currently in Phase III clinical trials for Colorectal Cancer.
• Adagrasib : Mirati Therapeutics Adagrasib is an investigational, highly selective, and potent oral small-molecule blocker of KRASG12C, designed to maintain target suppression, a feature that may be crucial for addressing KRASG12C-mutated cancers. The candidate is being tested alone and with other anti-cancer agents in patients with advanced KRASG12C-mutated colorectal cancer. It is under Phase III evaluation.
• Olaparib : Merck Sharp & Dohme LLC/Astrazeneca Olaparib is an experimental first-in-class Poly (ADP-ribose) polymerase (PARP) inhibitor and the initial targeted therapy that potentially leverages DNA damage response (DDR) pathway flaws, such as BRCA mutations, to selectively destroy cancer cells. Olaparib is co-developed and commercialized by AstraZeneca and Merck. The drug is in Phase III trials for Colorectal Cancer.
• DS-8201: Daiichi Sankyo DS-8201 is a proprietary antibody-drug conjugate (ADC), a smart chemotherapy consisting of a humanized HER2 antibody linked to a novel topoisomerase I inhibitor payload via a tetra-peptide linker. It aims to target and release chemotherapy within cancer cells, minimizing systemic exposure to the toxic agent compared to standard chemotherapy delivery. Developed in partnership with AstraZeneca. The drug is in Phase II clinical trials.
• Ompenaclid: Inspirna Ompenaclid is a pioneering oral small molecule blocker of the creatine transport channel SLC6A8, a novel target enriched in hypoxic conditions that supplies tumor cells with extra energy. Ompenaclid induces tumor shrinkage in CRC patients by triggering cell death. It utilizes Rgenix technology. The drug is in Phase II trials.
• LYL845: Lyell Immunopharma LYL845, an autologous tumor-infiltrating lymphocytes (TIL). It is given intravenously. It is developed using an ex vivo epigenetic reprogramming (Epi-R) technology platform and is currently in a Phase 1 trial for patients with relapsed or refractory metastatic colorectal cancer.
• RG6286: Genentech RG6286 (BLYG-8824A) is in development for relapsed or refractory, advanced, or metastatic colorectal cancer. It is a new chemical entity, delivered intravenously, and is under Phase 1 investigation.

The Colorectal Cancer Pipeline Report Provides Insights into

• The report furnishes comprehensive details on organizations advancing therapies for Colorectal Cancer, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Colorectal Cancer management.
• Colorectal Cancer Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Colorectal Cancer Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic collaborations), licensing deals, and funding information to drive future growth in the Colorectal Cancer market.

Explore more on Colorectal Cancer drug prospects in our innovative research and development efforts @ Colorectal Cancer Unmet Needs

Colorectal Cancer Companies Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.

Colorectal Cancer pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Colorectal Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the newest developments in Colorectal Cancer treatment by checking our site. Keep up with our progress in reshaping the future of disease @ Colorectal Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Colorectal Cancer Pipeline Report

• Coverage- Global
• Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences, Inc., Neogap Therapeutics AB, Criterium, Inc., Daiichi Sankyo, Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma, Ltd., BeyondBio Inc., Shanghai Henlius Biotech, Rottapharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
• Colorectal Cancer Therapies- Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
• Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For an extensive summary of our recent findings and upcoming strategies, review the complete Colorectal Cancer Pipeline details on our site @ Colorectal Cancer Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Colorectal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Comparative Analysis
8. XL092: Exelixis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Early Stage Products (Phase I)
12. LYL845: Lyell Immunopharma
13. Inactive Products
14. Colorectal Cancer Key Companies
15. Colorectal Cancer Key Products
16. Colorectal Cancer – Unmet Needs
17. Colorectal Cancer – Market Drivers and Barriers
18. Colorectal Cancer – Future Perspectives and Conclusion
19. Colorectal Cancer Analyst Views
20. Colorectal Cancer Key Companies
21. Appendix

About Us

DelveInsight is a premier market research and consulting firm focused on healthcare, offering high-quality intelligence and analysis to guide strategic decisions. Our team of seasoned industry professionals and deep expertise in life sciences and healthcare deliver tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Myotonic Dystrophy Pipeline Insight, 2025” report offers extensive analysis on over 20 companies and more than 22 pipeline drugs in the Myotonic Dystrophy treatment landscape. It features in-depth profiles of Myotonic Dystrophy pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses Myotonic Dystrophy therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Stay ahead with the latest insights! Obtain DelveInsight’s thorough Myotonic Dystrophy Pipeline Report to explore emerging treatments, key Companies, and future treatment landscapes @ Myotonic Dystrophy Pipeline Outlook Report

Key Takeaways from the Myotonic Dystrophy Pipeline Report

• On October 8, 2025, AMO Pharma Limited conducted a Phase 2/3 trial of patients (aged 6 to 16 years) with Congenital Myotonic Dystrophy (Congenital DM1).
• DelveInsight’s Myotonic Dystrophy pipeline report showcases a dynamic field with over 20 active contributors developing more than 22 pipeline treatments for Myotonic Dystrophy care.
• The top Myotonic Dystrophy Companies include AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, and others.
• Promising Myotonic Dystrophy Pipeline Therapies include AOC 1001, Mexiletine, PGN-EDODM1, SomatoKine/IPLEX, AOC 1001 (del-desiran), Tideglusib, ATX-01, and others.

Discover how the Myotonic Dystrophy treatment paradigm is evolving. Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Myotonic Dystrophy Clinical Trials and Studies

Myotonic Dystrophy Emerging Drugs Profile

• Mexiletine: Lupin Mexiletine is developed by Lupin under names like Mexiletine hydrochloride and Namuscla, is a class Ib antiarrhythmic drug mainly used for managing muscle stiffness linked to myotonic dystrophy. As a sodium channel blocker, mexiletine functions by inhibiting voltage-gated sodium channels in skeletal muscle fibers. This stops excessive sodium entry, which causes the delayed muscle relaxation seen in myotonia. By stabilizing the cell membrane and cutting down on repetitive firing in overexcitable muscle cells, mexiletine successfully reduces muscle stiffness and cramping, providing symptomatic relief for those with myotonic dystrophy. The drug is currently in Phase III clinical trials for myotonic dystrophy treatment.
• Pitolisant: Harmony Biosciences Pitolisant (WAKIX) is a selective histamine 3 (H3) receptor antagonist/inverse agonist. The mechanism of WAKIX is not fully understood; however, its effectiveness may stem from its action at H3 receptors, increasing the production and release of histamine, a neurotransmitter that promotes wakefulness. WAKIX was created and developed by Bioprojet (France). Harmony holds an exclusive license from Bioprojet to develop, manufacture, and commercialize pitolisant in the United States. The drug is under investigation in Phase II clinical trials for Myotonic Dystrophy.
• ARO-DM1: Arrowhead Pharmaceuticals, Inc. ARO-DM1 is an RNA interference (RNAi) conjugate engineered to specifically suppress DMPK mRNA in skeletal muscle. Research indicates that silencing abnormally transcribed DMPK mRNA with ARO-DM1 may stop CUGexp-related spliceopathies in DM1 patients, leading to enhanced muscle strength and function. It falls under RNA therapeutics. The candidate is delivered intravenously. ARO-DM1 is in Phase I development for myotonic dystrophy.

The Myotonic Dystrophy pipeline report provides insights into

• The report delivers comprehensive details on firms advancing therapies for Myotonic Dystrophy, including the cumulative treatments each company is pursuing.
• It reviews diverse therapeutic candidates categorized into initial, intermediate, and advanced development stages for Myotonic Dystrophy management.
• Myotonic Dystrophy Companies are focused on precision therapeutics with ongoing and paused (inactive or terminated) programs.
• Myotonic Dystrophy Drugs in development, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive examination of partnerships (business alliances and academic ties), licensing arrangements, and funding details to propel future progress in the Myotonic Dystrophy market.

Get a detailed analysis of the latest innovations in the Myotonic Dystrophy pipeline. Explore DelveInsight’s expert-driven report today! @ Myotonic Dystrophy Unmet Needs

Myotonic Dystrophy Companies AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, and others.

The Myotonic Dystrophy pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Myotonic Dystrophy Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Obtain DelveInsight’s latest report to gain strategic insights into upcoming therapies and key Myotonic Dystrophy Developments @ Myotonic Dystrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Myotonic Dystrophy Pipeline Report

• Coverage- Global
• Myotonic Dystrophy Companies- AMO Pharma, Lupin, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Pepgen Corporation, Aparito, and others.
• Myotonic Dystrophy Pipeline Therapies- AOC 1001, Mexiletine, PGN-EDODM1, SomatoKine/IPLEX, AOC 1001 (del-desiran), Tideglusib, ATX-01, and others.
• Myotonic Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myotonic Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Myotonic Dystrophy drug development? Find out in DelveInsight’s exclusive Pipeline Report-access it now! @ Myotonic Dystrophy Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Myotonic Dystrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myotonic Dystrophy- DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mexiletine: Lupin
9. Mid-Stage Products (Phase II)
10. Pitolisant: Harmony Biosciences
11. Early Stage Products (Phase I)
12. Comparative Analysis
13. ARO-DM1: Arrowhead Pharmaceuticals, Inc.
14. Preclinical and Discovery Stage Products
15. Drug name: Company name
16. Inactive Products
17. Myotonic Dystrophy Key Companies
18. Myotonic Dystrophy Key Products
19. Myotonic Dystrophy- Unmet Needs
20. Myotonic Dystrophy- Market Drivers and Barriers
21. Myotonic Dystrophy- Future Perspectives and Conclusion
22. Myotonic Dystrophy Analyst Views
23. Myotonic Dystrophy Key Companies
24. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

 

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Short Bowel Syndrome Pipeline Insight 2025” report delivers extensive analysis on over 18 companies and more than 20 pipeline drugs in the Short Bowel Syndrome treatment landscape. It includes thorough profiles of Short Bowel Syndrome pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Short Bowel Syndrome therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this area.

Explore our cutting-edge advancements in Short Bowel Syndrome studies. Get more details on our pioneering pipeline now! @ Short Bowel Syndrome Pipeline Outlook

Key Takeaways from the Short Bowel Syndrome Pipeline Report

• On August 22, 2025, Hanmi Pharmaceutical Company Limited launched a Phase 2 trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of subcutaneous delivery of HM15912 (sonefpeglutide) in adults with SBS-related intestinal failure (SBS-IF). The trial includes a screening phase, a run-in period, a 6-month main treatment phase, a 7-month extended treatment period, and a 1-month safety monitoring phase.
• DelveInsight’s Short Bowel Syndrome pipeline report illustrates a vibrant arena with over 18 active contributors developing more than 20 pipeline treatments for Short Bowel Syndrome care.
• The prominent Short Bowel Syndrome Companies include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
• Promising Short Bowel Syndrome Pipeline Therapies include PJ009, Apraglutide, Teduglutide, Glepaglutide, Teduglutide 0.05mg/kg, Pancreatic Enzyme, HM15912, ZP1848, FE203799, and others.

Stay updated on the latest innovations in Short Bowel Syndrome treatments. Access for updates and join the advancement in Endocrinology and Metabolic Disorders Care @ Short Bowel Syndrome Clinical Trials Assessment

Short Bowel Syndrome Emerging Drugs Profile

• Glepaglutide: Zealand Pharma Glepaglutide is a prolonged-action GLP-2 analog being developed as a potential therapy for short bowel syndrome (SBS). Glepaglutide is formulated as a liquid in an autoinjector for subcutaneous use, intended to minimize or remove the reliance on parenteral nutrition in individuals with SBS. The product is currently in Phase III development for Short Bowel Syndrome.

The Short Bowel Syndrome Pipeline Report provides insights into

• The report furnishes comprehensive details on organizations advancing therapies for Short Bowel Syndrome, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Short Bowel Syndrome management.
• Short Bowel Syndrome Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Short Bowel Syndrome Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic collaborations), licensing deals, and funding information to drive future growth in the Short Bowel Syndrome market.

Explore more on Short Bowel Syndrome drug prospects in our innovative research and development efforts @ Short Bowel Syndrome Unmet Needs

Short Bowel Syndrome Companies VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.

Short Bowel Syndrome pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Intravenous

Short Bowel Syndrome Products have been categorized under various Molecule types such as

• Peptide
• Protein
• Propylene glycols
• Cell Therapy

Discover the newest developments in Short Bowel Syndrome treatment by checking our site. Keep up with our progress in reshaping Endocrinology and Metabolic Disorders @ Short Bowel Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Short Bowel Syndrome Pipeline Report

• Coverage- Global
• Short Bowel Syndrome Companies- VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
• Short Bowel Syndrome Pipeline Therapies- PJ009, Apraglutide, Teduglutide, Glepaglutide, Teduglutide 0.05mg/kg, Pancreatic Enzyme, HM15912, ZP1848, FE203799, and others.
• Short Bowel Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Short Bowel Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For an extensive summary of our recent findings and upcoming strategies, review the complete Short Bowel Syndrome Pipeline details on our site @ Short Bowel Syndrome Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Short Bowel Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Short Bowel Syndrome – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Glepaglutide: Zealand Pharma
9. Mid Stage Products (Phase II)
10. HM 15912: Hanmi Pharmaceutical
11. Mid Stage Products (Phase II)
12. Vurolenatide: 9 Meters Biopharma
13. Early Stage Products (Phase I)
14. SEFA-6179: NorthSea Therapeutics
15. Preclinical and Discovery Stage Products
16. GLP2-ELP: PhaseBio Pharmaceuticals
17. Inactive Products
18. Short Bowel Syndrome Key Companies
19. Short Bowel Syndrome Key Products
20. Short Bowel Syndrome- Unmet Needs
21. Short Bowel Syndrome- Market Drivers and Barriers
22. Short Bowel Syndrome- Future Perspectives and Conclusion
23. Short Bowel Syndrome Analyst Views
24. Short Bowel Syndrome Key Companies
25. Appendix

About Us

DelveInsight is a premier market research and consulting firm focused on healthcare, offering high-quality intelligence and analysis to guide strategic decisions. Our team of seasoned industry professionals and deep expertise in life sciences and healthcare deliver tailored research services and insights globally. Connect with us for accurate, timely data to stay competitive.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “RNA Interference Pipeline Insight 2025” report delivers extensive insights into over 20 companies and 90+ pipeline drugs in the RNA Interference landscape. It encompasses profiles of RNA Interference pipeline drugs across clinical and nonclinical phases. The report also evaluates RNA Interference therapeutics by product type, development stage, administration route, and molecule type, while spotlighting inactive pipeline products.

Uncover the newest treatments and options in the RNA Interference Pipeline. Access DelveInsight’s detailed report now! @ RNA Interference Pipeline Outlook

Key Takeaways from the RNA Interference Pipeline Report

• On August 13, 2025, Novartis Pharmaceuticals disclosed a Phase III study to assess the safety, tolerability, and effectiveness of inclisiran in children aged 2 to [incomplete in original, assuming continuation].
• DelveInsight’s RNA Interference Pipeline report highlights a dynamic field with 20+ active participants developing 90+ therapies for RNA Interference applications.
• Leading RNA Interference Companies include Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/Biogen, Mallinckrodt/Silence Therapeutics, and others.
• Promising RNA Interference Therapies such as Inclisiran, Saline, I5NP, Bevasiranib, and others are advancing.

Gain insights into RNA Interference Clinical Trials, emerging treatments, and key players with DelveInsight @ RNA Interference Treatment Drugs

RNA Interference Emerging Drugs Profile

• Vutrisiran: Alnylam Pharmaceuticals
  Vutrisiran is an investigational subcutaneous RNAi therapeutic for ATTR amyloidosis, including hATTR and wtATTR. It targets and silences messenger RNA to prevent production of wild-type and variant transthyretin (TTR) protein. Quarterly or biannual dosing may reduce amyloid deposits and restore tissue function. It uses Alnylam’s ESC-GalNAc-conjugate platform for enhanced potency and stability.
• Cemdisiran: Alnylam Pharmaceuticals
  Cemdisiran is an RNAi therapeutic targeting complement component C5 for complement-mediated diseases. Dysregulation of the complement system leads to complications in conditions like PNH, aHUS, myasthenia gravis, and others. As a subcutaneous option, it leverages ESC-GalNAc technology for potency and durability. Partner Regeneron is conducting Phase III studies in myasthenia gravis and PNH.
• SR061: Suzhou Ribo Life Science
  SR061 is a siRNA that inhibits Caspase 2 expression via RNAi, preventing retinal ganglion cell apoptosis and axonal degeneration to protect vision in diseases like NAION. It aims to be the first neuroprotective agent for NAION. Phase I/IIa and Phase II/III studies are complete, with a confirmatory Phase III underway.
• ARO-APOC3: Arrowhead Pharmaceuticals
  ARO-APOC3 is a subcutaneous RNAi therapeutic reducing Apolipoprotein C-III production, a regulator of triglyceride metabolism. It may lower VLDL synthesis and improve TRL clearance. In development for severe hypertriglyceridemia, FCS, and mixed dyslipidemia. Phase III for FCS, Phase II for others, with Phase I completed.
• DCR-PHXC: Dicerna Pharmaceuticals
  DCR-PHXC is the only RNAi candidate for all primary hyperoxaluria types, using GalXC technology for liver-targeted silencing. Evaluated in the PHYOX program across phases.

The RNA Interference Pipeline Report Provides Insights into:

• Detailed information on companies advancing RNA Interference therapies, with totals per company.
• Segmentation of candidates into early, mid, and late stages for RNA Interference treatment.
• RNA Interference Companies engaged in targeted development, including active and inactive projects.
• RNA Interference Drugs categorized by phase, route, target, monotherapy or combination, mechanism, and molecule type.
• Comprehensive analysis of partnerships (corporate and academic), licensing, and funding for RNA Interference market progress.

Discover innovative therapies and trials in the RNA Interference Pipeline. Obtain DelveInsight’s detailed report today! @ New RNA Interference Drugs

RNA Interference Companies
Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/Biogen, Mallinckrodt/Silence Therapeutics, and others.

The RNA Interference pipeline report evaluates therapeutics by Route of Administration, grouping them as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical

Products are classified by Molecule Type, including:

• Oligonucleotide
• Peptide
• Small molecule

Explore new RNA Interference drugs, developments, and major players with DelveInsight’s analysis @ RNA Interference Market Drivers and Barrier

Scope of the RNA Interference Pipeline Report

• Coverage: Global
• RNA Interference Companies: Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/Biogen, Mallinckrodt/Silence Therapeutics, and others.
• RNA Interference Therapies: Inclisiran, Saline, I5NP, Bevasiranib, and others.
• RNA Interference Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• RNA Interference Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Secure DelveInsight’s comprehensive RNA Interference Pipeline report now! @ RNA Interference Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. RNA Interference: Overview
4. Pipeline Therapeutics
5. RNA Interference Therapeutic Assessment
6. RNA Interference – DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Vutrisiran: Alnylam Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Cemdisiran: Alnylam Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name : Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. RNA Interference Key Companies
21. RNA Interference Key Products
22. RNA Interference – Unmet Needs
23. RNA Interference Market Drivers
24. RNA Interference Barriers
25. RNA Interference: Future Perspectives and Conclusion
26. RNA Interference Analyst Views
27. RNA Interference Key Companies
28. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us 

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025” report offers detailed analysis on over 5 companies and 5+ pipeline drugs in the Cough in Idiopathic Pulmonary Fibrosis (IPF) landscape. It includes profiles of Cough in Idiopathic Pulmonary Fibrosis pipeline drugs across clinical and nonclinical phases. The report also evaluates Cough in Idiopathic Pulmonary Fibrosis pipeline therapeutics by product type, development stage, administration route, and molecule type, while highlighting inactive pipeline products.

Grab our full report to dive into clinical-stage progress and key partnerships reshaping the field! @ Cough in Idiopathic Pulmonary Fibrosis Pipeline Outlook Report

Key Takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report

• On October 14, 2025, Boehringer Ingelheim initiated a study for adults 40+ with idiopathic pulmonary fibrosis (IPF). Participants can enroll if untreated or on stable therapy for at least 3 months. The goal is to assess BI 1819479’s effectiveness, testing three doses.
• DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis pipeline report reveals a vibrant space with 5+ active innovators developing 5+ therapies for Cough in Idiopathic Pulmonary Fibrosis management.
• Leading Cough in Idiopathic Pulmonary Fibrosis Companies include Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma, and others.
• Promising Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies such as Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate), and others are gaining traction.

Discover how top Cough in Idiopathic Pulmonary Fibrosis Companies are setting up for success in the changing pharma world—get the complete report now! @ Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs Profile

• Haduvio (nalbuphine ER): Trevi Therapeutics
• Haduvio (nalbuphine ER) tackles chronic cough by targeting two key receptors in central and peripheral nerves. It acts as an agonist for the kappa opioid receptor and an antagonist for the mu opioid receptor. This dual action along the cough pathway could work no matter the trigger’s origin. It’s in Phase II for Cough in Idiopathic Pulmonary Fibrosis (IPF).

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report offers insights into:

• Comprehensive details on companies advancing Cough in Idiopathic Pulmonary Fibrosis therapies, with totals per company.
• Segmentation of candidates into early, mid, and late stages for Cough in Idiopathic Pulmonary Fibrosis treatment.
• Cough in Idiopathic Pulmonary Fibrosis Companies focused on targeted therapies, including active and inactive projects.
• Cough in Idiopathic Pulmonary Fibrosis Drugs categorized by phase, route, target, solo or combo, action mechanism, and molecule type.
• In-depth analysis of partnerships (corporate and academic), licensing, and funding to drive the Cough in Idiopathic Pulmonary Fibrosis market.

From initial research to advanced Cough in Idiopathic Pulmonary Fibrosis Clinical Trials, our report covers major players, novel approaches, and upcoming Emerging Drugs. Stay ahead—access it today! @ Cough in Idiopathic Pulmonary Fibrosis Treatment Drugs

Cough in Idiopathic Pulmonary Fibrosis Companies
Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma, and others.

The Cough in Idiopathic Pulmonary Fibrosis (IPF) pipeline report evaluates therapeutics by Route of Administration, grouping them as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Products are classified by Molecule Type, including:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Keep current with the latest Cough in Idiopathic Pulmonary Fibrosis Pipeline Insights—secure our report for a thorough look at future therapeutics! @ Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspectives

Scope of the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report

• Coverage: Global
• Cough in Idiopathic Pulmonary Fibrosis Companies: Trevi Therapeutics, Algernon Pharmaceuticals, Melius Pharma, and others.
• Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapies: Orvepitant Maleate, Gefapixant, BI 1839100, PA101, ME-015 (Suplatast Tosilate), and others.
• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get answers from our Pipeline Insights report, with extensive coverage of Clinical Trials, regulatory shifts, and emerging breakthroughs. Secure it now to lead in pharma innovation! @ Cough in Idiopathic Pulmonary Fibrosis Emerging Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Cough in Idiopathic Pulmonary Fibrosis (IPF): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cough in Idiopathic Pulmonary Fibrosis (IPF) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Mid Stage Products (Phase II)
10. Haduvio (nalbuphine ER): Trevi Therapeutics
11. Early Stage Products (Phase I)
12. Drug name: Company name
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
17. Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Products
18. Cough in Idiopathic Pulmonary Fibrosis (IPF) – Unmet Needs
19. Cough in Idiopathic Pulmonary Fibrosis (IPF) – Market Drivers and Barriers
20. Cough in Idiopathic Pulmonary Fibrosis (IPF) – Future Perspectives and Conclusion
21. Cough in Idiopathic Pulmonary Fibrosis (IPF) Analyst Views
22. Cough in Idiopathic Pulmonary Fibrosis (IPF) Key Companies
23. Appendix

About Us

DelveInsight is a premier healthcare market research and consulting firm, delivering top-tier intelligence and analysis for strategic decisions. Our experts in life sciences and healthcare provide tailored solutions and global insights. Connect for premium, current data to stay ahead.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Graft versus Host Disease Pipeline Insight 2025” report is packed with thrilling details on over 45 Graft Versus Host Disease Companies and 50+ pipeline drugs shaking up the GVHD landscape. We’ve dissected drug profiles from lab experiments to clinical trials, plus a full evaluation of therapies by category, phase, delivery method, and molecule type. And yep, we cover the inactive ones too for the complete lowdown.

Eager to catch the hottest updates in the Graft versus Host Disease Pipeline? Let’s jump right in! @ Graft versus Host Disease Pipeline Outlook Report

Key Takeaways from the Graft versus Host Disease Pipeline Report

• On October 14, 2025, Incyte Corporation launched a study comparing Tacrolimus/Methotrexate/Ruxolitinib against Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in non-myeloablative/reduced intensity conditioning allogeneic peripheral blood stem cell transplantation.
• DelveInsight’s Graft Versus Host Disease pipeline report showcases a dynamic arena with 45+ active trailblazers developing 50+ therapies for Graft Versus Host Disease management.
• Leading Graft Versus Host Disease Companies include Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen, and more.
• Exciting Graft Versus Host Disease Therapies like Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others are stealing the spotlight.

Curious who’s driving the innovation wave in Graft versus Host Disease? Plunge into the complete pipeline details! @ Graft versus Host Disease Clinical Trials Assessment

The Graft versus Host Disease Pipeline Report delivers a disease summary, pipeline overview, and assessment of top therapies. It also shines a light on unmet needs in Graft versus Host Disease.

Graft versus Host Disease Overview Graft versus host disease (GVHD) is a tough complication where donor immune cells attack the recipient’s body after an allogeneic stem cell or bone marrow transplant. It happens because the donor’s cells see the recipient’s as invaders, sparking an immune fight. GVHD mainly involves donor T-cells and splits into acute and chronic types. Acute GVHD pops up within 100 days, showing skin rashes, jaundice, liver issues, and diarrhea.

Graft versus Host Disease Emerging Drugs

• Itolizumab: Equillium
  Itolizumab is a cutting-edge monoclonal antibody targeting the CD6-ALCAM pathway, key in controlling T-cell activity in inflammatory diseases. Launched in India as ALZUMAB in 2013, it got emergency approval for COVID-19 cytokine storms. Now in Phase III for acute graft-versus-host disease (aGVHD).
• ABSK021: Abbisko Therapeutics
  Pimicotinib (ABSK021), Abbisko’s own oral CSF-1R inhibitor, is highly selective and potent. Exploring solid tumors, it has NMPA approval for a Phase II in chronic graft-versus-host disease. In Phase II for Chronic GVHD.
• SYN-004: Theriva Biologics
  SYN-004 (ribaxamase) is an oral preventive treatment that breaks down IV beta-lactam antibiotics in the gut to preserve microbiome balance against acute graft-versus-host-disease (aGVHD) in HCT recipients. Antibiotic gut damage links to CDI, VRE, bacteremia, and aGVHD. In Phase I/II for GVHD.
• SER-155: Seres Therapeutics
  SER-155 is an oral fermented bacterial mix to bolster immunocompromised patients. It boosts microbiome roles for better survival, fewer infections, and less graft versus host disease (GvHD) in allo-HSCT. Based on human data, it strengthens gut microbiome, immunity, and fights GI infections and bacteremia. In Phase I for GvHD.

If you’re following Graft versus Host Disease Clinical trials, this update is essential. Check out the innovations! @ Graft versus Host Disease Treatment Drugs

Graft versus Host Disease Companies
Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen, and others.

The Graft versus Host Disease Pipeline report offers insights into:

• Deep dives into companies brewing Graft versus Host Disease therapies, with totals per company.
• Breakdown of candidates into early, mid, and late stages for Graft versus Host Disease treatment.
• Graft versus Host Disease Companies chasing targeted therapies, including active and inactive efforts.
• Graft versus Host Disease Drugs sorted by phase, route, target, solo or combo, action mechanism, and molecule type.
• Comprehensive review of partnerships (biz-to-biz and academic), licensing, and funding to advance the Graft versus Host Disease market.

The GVHD Pipeline report evaluates therapeutics by Route of Administration, grouping them as:

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Products are classified by Molecule Type, including:

• Monoclonal antibody
• Small molecule
• Peptide

From novel drug prospects to market intel, the Graft versus Host Disease Pipeline Report has everything—grab it today! @ Graft versus Host Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Graft versus Host Disease Pipeline Report

• Coverage: Global
• Graft versus Host Disease Companies: Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, Amgen, and others.
• Graft Versus Host Disease Therapies: Ibrutinib, Prednisone, ruxolitinib, Axatilimab, GDC-8264, Ruxolitinib, Defibrotide, and others.
• Graft versus Host Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Graft versus Host Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Lead the charge in Healthcare Research—uncover the future of Graft versus Host Disease treatment in this in-depth guide! @ Graft versus Host Disease Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Graft versus host disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Graft versus host disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Itolizumab: Equillium
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ABSK021: Abbisko Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. SER-155: Seres Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Graft versus host disease Key Companies
21. Graft versus host disease Key Products
22. Graft versus host disease – Unmet Needs
23. Graft versus host disease – Market Drivers and Barriers
24. Graft versus host disease – Future Perspectives and Conclusion
25. Graft versus host disease Analyst Views
26. Graft versus host disease Key Companies
27. Appendix

About Us

DelveInsight is a top-tier healthcare market research and consulting firm, equipping clients with superior intelligence and analysis for strategic decisions. Our life sciences and healthcare experts deliver tailored solutions and global insights. Reach out for premium, up-to-date data to stay ahead.

Contact us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “COVID-19 Pipeline Insight 2025” report offers extensive analysis on over 180 companies and more than 200 pipeline drugs in the COVID-19 treatment landscape. It features in-depth profiles of COVID-19 pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses COVID-19 therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Discover the newest medications and treatment avenues in the COVID-19 Pipeline. Explore DelveInsight’s thorough report now! @ COVID-19 Pipeline Outlook

Key Highlights from the COVID-19 Pipeline Report

• On August 27, 2025, CytoDyn Inc. disclosed the launch of a Phase 2b/3 trial to assess the safety and effectiveness of leronlimab (PRO 140) in individuals with severe or critical respiratory symptoms from coronavirus 2019 infection. In this study, participants will be randomly assigned to receive either weekly 700 mg doses of leronlimab (PRO 140) or a placebo. Both leronlimab (PRO 140) and the placebo will be given subcutaneously.
• DelveInsight’s COVID-19 Pipeline report showcases a dynamic field with over 180 active contributors developing more than 200 pipeline treatments for COVID-19 care.
• The top COVID-19 Companies include Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.
• Promising COVID-19 Pipeline Therapies include Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Gain insights into COVID-19 clinical trials, emerging treatments, and key companies via DelveInsight @ COVID-19 Treatment Drugs

COVID-19 Emerging Drugs Profile

• DAS181: Ansun Pharm DAS181 is a recombinant sialidase enzyme that functions by stripping sialic acids from lung surfaces, preventing influenza from attaching and infecting. This halts the viral cycle, aiding recovery. By focusing on the host instead of the virus, DAS181 is less prone to resistance from viral mutations, and since it targets the host, it applies to other sialic acid-dependent viruses. DAS181 is administered via nebulization using Aerogen Solo technology. The U.S. Food and Drug Administration (FDA) has awarded Fast Track and Breakthrough Therapy status to DAS181. The drug is currently in Phase III clinical trials for COVID-19 treatment.
• Sarconeos (BIO101): Biophytis Sarconeos (BIO101) is an oral small molecule under development for neuromuscular disorders. From cell and animal studies, it is thought to enhance biological resilience by stimulating the MAS receptor, potentially boosting muscle function and maintaining strength, mobility, and breathing in age-related and wasting conditions. The drug is in Phase III clinical trials for COVID-19.
• MP1032: MetrioPharm MP1032 is a distinctive small molecule that targets overactive immune cell responses by influencing a core metabolic pathway in stimulated immune cells. Mitochondria in these cells ramp up energy production upon activation, producing reactive oxygen species (ROS) and raising intracellular pH. MP1032 activates only in high pH environments, acting as an ROS neutralizer to correct abnormally high ROS levels (oxidative stress). When pH normalizes, the drug deactivates, avoiding interference with essential ROS in other cells, ensuring a strong safety profile. This self-regulating action positions MP1032 as a pioneering anti-inflammatory agent. The drug is in Phase II development for COVID-19.
• GLS-5310: GeneOne Life Science GLS-5310 is a DNA vaccine encoding the spike (S) protein and another SARS-CoV-2 antigen. It is being advanced with backing from the Korean government via the Centers for Disease Control and Prevention as part of a national COVID-19 vaccine initiative. GLS-5310 is in preclinical stages. The drug is in Phase I/II trials for COVID-19.
• S-892216: Shionogi S-892216, created by Sumitomo Pharma, is explored for treating COVID-19-associated acute respiratory distress syndrome (ARDS). As a serotonin 5-HT2A receptor agonist, it seeks to modulate immune responses and curb severe inflammation linked to critical COVID-19 cases. This compound introduces a fresh strategy for managing cytokine storms and enhancing results in seriously ill patients. The drug is in Phase I clinical development for COVID-19.

The COVID-19 Pipeline Report Provides Insights into

• The report delivers comprehensive details on firms advancing therapies for COVID-19, including the cumulative treatments each company is pursuing.
• It reviews diverse therapeutic candidates categorized into initial, intermediate, and advanced development stages for COVID-19 management.
• COVID-19 Companies are focused on precision therapeutics with ongoing and paused (inactive or terminated) programs.
• COVID-19 Drugs in development, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive examination of partnerships (business alliances and academic ties), licensing arrangements, and funding details to propel future progress in the COVID-19 market.

Explore innovative treatments and clinical trials in the COVID-19 Pipeline. Obtain DelveInsight’s detailed report today! @ New COVID-19 Drugs

COVID-19 Companies Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.

COVID-19 pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

COVID-19 Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about emerging COVID-19 drugs, pipeline advancements, and key companies with DelveInsight’s expert analysis @ COVID-19 Market Drivers and Barriers

Scope of the COVID-19 Pipeline Report

• Coverage- Global
• COVID-19 Companies- Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.
• COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.
• COVID-19 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• COVID-19 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s comprehensive pipeline report now! @ COVID-19 Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. DAS181: Ansun Pharm
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. MP1032: MetrioPharm
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. GLS-5310: GeneOne Life Science
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. COVID-19 Key Companies
20. COVID-19 Key Products
21. COVID-19- Unmet Needs
22. COVID-19- Market Drivers and Barriers
23. COVID-19- Future Perspectives and Conclusion
24. COVID-19 Analyst Views
25. COVID-19 Key Companies
26. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Familial Mediterranean Fever Pipeline Insight 2025” report delivers extensive analysis on over 3 companies and more than 3 pipeline drugs in the Familial Mediterranean Fever treatment landscape. It includes thorough profiles of Familial Mediterranean Fever pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Familial Mediterranean Fever therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this area.

Discover the newest medications and treatment avenues in the Familial Mediterranean Fever Pipeline. Explore DelveInsight’s detailed report now! @ Familial Mediterranean Fever Pipeline Outlook

Key Highlights from the Familial Mediterranean Fever Pipeline Report

• On August 27, 2025, the University of São Paulo General Hospital launched a Phase 4 randomized prospective trial with adult patients suffering from autoimmune rheumatic diseases (ARDs). Participants will get two intramuscular doses of RZV spaced six weeks apart. A control group (CG) of non-immunosuppressed individuals aged ≥50 years will be included, at a ratio of three patients to one control. ARDs patients will be randomly divided into groups P1 and P2. Both CG and P1 groups will receive the vaccine right after randomization, on Day 0 (D0) and Day 42 (D42).
• DelveInsight’s Familial Mediterranean Fever Pipeline report illustrates a vibrant arena with over 3 active contributors developing more than 3 pipeline treatments for Familial Mediterranean Fever care.
• The prominent Familial Mediterranean Fever Companies include Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals, and others.
• Promising Familial Mediterranean Fever Pipeline Therapies include Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast, and others.

Gain insights into clinical trials, emerging treatments, and key companies via DelveInsight @ Familial Mediterranean Fever Treatment Drugs

Familial Mediterranean Fever Emerging Drugs Profile

• Tocilizumab: Roche Tocilizumab is a recombinant humanized monoclonal antibody that inhibits the IL-6 receptor, employed for managing inflammatory and autoimmune disorders.

The Familial Mediterranean Fever Pipeline Report Provides Insights into

• The report furnishes comprehensive details on organizations advancing therapies for Familial Mediterranean Fever, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Familial Mediterranean Fever management.
• Familial Mediterranean Fever Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Familial Mediterranean Fever Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic collaborations), licensing deals, and funding information to drive future growth in the Familial Mediterranean Fever market.

Explore innovative treatments and clinical trials in the Familial Mediterranean Fever Pipeline. Obtain DelveInsight’s detailed report today! @ New Familial Mediterranean Fever Drugs

Familial Mediterranean Fever Companies Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals, and others.

Familial Mediterranean Fever pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Subcutaneous
• Intravenous
• Oral
• Parenteral
• Intramuscular
• Molecule Type

Familial Mediterranean Fever Products have been categorized under various Molecule types such as

• Small molecules
• Peptides
• Polymer
• Gene Therapy
• Monoclonal antibodies
• Product Type

Learn about emerging drugs, pipeline advancements, and key companies with DelveInsight’s expert analysis @ Familial Mediterranean Fever Market Drivers and Barriers

Scope of the Familial Mediterranean Fever Pipeline Report

• Coverage- Global
• Familial Mediterranean Fever Companies- Roche, Novartis Pharmaceuticals, R-Pharm International LLC, Soligenix, Amgen, Mitsubishi Tanabe Pharma Corporation, Nobel Pharmaceuticals, and others.
• Familial Mediterranean Fever Pipeline Therapies- Canakinumab, RPH-104, ACZ885, Dusquetide, AIN457, Apremilast, Infliximab, Apremilast, and others.
• Familial Mediterranean Fever Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Familial Mediterranean Fever Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s comprehensive pipeline report now! @ Familial Mediterranean Fever Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Familial Mediterranean Fever: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Familial Mediterranean Fever – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Familial Mediterranean Fever Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. Tocilizumab: Roche
13. Drug profiles in the detailed report…..
14. Pre-clinical and Discovery Stage Products
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Familial Mediterranean Fever Key Companies
18. Familial Mediterranean Fever Key Products
19. Familial Mediterranean Fever- Unmet Needs
20. Familial Mediterranean Fever- Market Drivers and Barriers
21. Familial Mediterranean Fever- Future Perspectives and Conclusion
22. Familial Mediterranean Fever Analyst Views
23. Familial Mediterranean Fever Key Companies
24. Appendix

About Us

DelveInsight is a premier market research and consulting firm focused on healthcare, offering high-quality intelligence and analysis to guide strategic decisions. Our team of seasoned industry professionals and deep expertise in life sciences and healthcare deliver tailored research services and insights globally. Connect with us for accurate, timely data to stay competitive.

Contact Us

Kanishk

kkumar@delveinsight.com